Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

JAK2 fusion genes are rare but recurrent abnormalities associated with diverse, clinically heterogeneous hematologic malignancies. Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN). Ruxolitinib-treated Ba/F3...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Chase, Andrew, Bryant, Catherine, Score, Joannah, Haferlach, Claudia, Grossmann, Vera, Schwaab, Juliana, Hofmann, Wolf-Karsten, Reiter, Andreas, Cross, Nicholas C.P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2013
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3659945/
https://ncbi.nlm.nih.gov/pubmed/22875628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.067959
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller